Celentyx Ltd is a ‘boutique’ CRO providing bespoke drug discovery services focused on human immunology across a broad range of therapeutic areas including autoimmunity, COVID-19, inflammation, immuno-oncology, fibrosis and neuroinflammation. Celentyx has a highly experienced scientific team that develops and provides assays using human primary cells at all stages of the drug discovery pipeline. Situated in close proximity to major hospitals and blood services (with established partnerships), assays can be performed at scale using blood and tissue from healthy volunteers and patients with defined disease including deep access to their clinical records. Celentyx has well-established assay platforms in multi-colour flow-cytometry, Cytof, high-content imaging, multiplex supernatant analysis (Luminex), super-resolution microscopy as well as proteomic and molecular biology capability, enabling high-resolution analysis of the human immune system for target discovery, screening, candidate selection, mechanism of action, and biomarker studies. Celentyx is based in the UK (Oxford and Birmingham) and in addition to internationally recognised scientists within the company, benefits from the world-leading expertise of neighbouring translational medicine departments at the Universities of Oxford and Birmingham.